Shocking the cancer: extreme hormone swings tested for tough prostate cases
NCT ID NCT04558866
Summary
This study is testing a new approach called 'extreme bipolar androgen therapy' for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It alternates high doses of testosterone with a drug that blocks testosterone's effects, aiming to confuse and slow the cancer's growth. The trial will measure how long patients live without their cancer getting worse and monitor their quality of life and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)
Rio de Janeiro, Rio de Janeiro, 22.250-905, Brazil
-
HIAE - Hospital Israelita Albert Einstein
São Paulo, São Paulo, 05.653-000, Brazil
-
HMV - Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, 90.035-000, Brazil
-
Hospital São Rafael - Oncologia D'Or BA
Salvador, Estado de Bahia, 41.253-190, Brazil
-
Hospital Sírio-Libanês DF
Brasília, Federal District, 70.200-730, Brazil
-
Hospital Sírio-Libanês SP
São Paulo, São Paulo, 01.308-050, Brazil
Conditions
Explore the condition pages connected to this study.